The Effects of Campath 1H upon Graft-Versus-Host Disease, Infection, Relapse, and Immune Reconstitution in Recipients of Pediatric Unrelated Transplants

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 5, 2007, Pages 584-593

  Shah, Ami J ^a,b   Kapoor, Neena ^a,b   Crooks, Gay M ^a,b   Weinberg, Kenneth I ^c   Azim, Hisham Abdel ^a,b   Killen, Renna ^b   Kuo, Lily ^b   Rushing, Teresa ^b   Kohn, Donald B ^a,b   Parkman, Robertson ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Campath 1H; Graft versus host disease; Hematopoietic stem cell transplantation; Immune reconstitution

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CALCINEURIN INHIBITOR; CD3 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ETOPOSIDE; METHOTREXATE; PHYTOHEMAGGLUTININ; PROCARBAZINE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADENOVIRUS; ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BK VIRUS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS; DEMOGRAPHY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 6; IMMUNE RESPONSE; INCIDENCE; INFECTION; INFECTION RISK; INFLUENZA; INTESTINE INFECTION; LEUKEMIA; LEUKEMIA RELAPSE; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PATIENT COMPLIANCE; PEDIATRICS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE RISK; REPEATED DRUG DOSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETROSPECTIVE STUDY; RISK REDUCTION; RNA VIRUS INFECTION; ROTAVIRUS; SAMPLE SIZE; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; T LYMPHOCYTE; TOXOPLASMOSIS; URINARY TRACT INFECTION; VIRUS INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD3; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34247151101     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.01.076     Document Type: Article

References (26)

1. Buggins A.G.S., Mufti G.J., Salisbury J., et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 100 (2002) 1715-1720
2. Gilleece M.H., and Dexter T.M. Effect of Campath 1-H antibody on human hematopoietic progenitors in vitro. Blood 82 (1993) 807-812
3. Williams R.J., Clarke E., Blair A., et al. Impact on T cell depletion and CD34+cell recovery using humanized C52 monoclonal antibody (CAMPATH 1H) in BM and PBSC collections: comparison with CAMPATH 1M and CAMPATH 1G. Cytotherapy 2 (2000) 5-14
4. Hale G., Jacobs P., Wood L., et al. CD52 Antibodies for prevention of graft versus host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. BMT 26 (2000) 69-76
5. Kottaridis P.D., Milligan D.W., Chopra R., et al. In vivo Campath 1H prevents graft versus host disease following nonmyeloablative stem cell transplantation. Blood 96 (2000) 2419-2425
6. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
7. Myers G.D., Kranes R.A., Weiss H., et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 36 (2005) 1001-1008
8. Chakrabarti S., Mautner V., Osman H., et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100 (2002) 1619-1627
9. Chakrabarti S., Mackinnon S., Chopra R., et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99 (2002) 4357-4363
10. Chakraverty R., Robinson S., Peggs K., et al. Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation. Bone Marrow Transplant. 28 (2001) 827-834
11. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18 (1974) 295-304
12. Weinberg K., Hershfield M.S., Bastian J., et al. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene modified adenosine deaminase. J Clin Invest. 92 (1993) 586-602
13. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 135 (1958) 185
14. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft versus host disease: initial treatment. Blood 76 (1990) 1464-1472
15. Roy J., McGlave P.B., Filopovich A.H., et al. Acute graft versus host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant. 10 (1992) 77-82
16. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute GVHD after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75 (1990) 1024-1030
17. Lee S.J., Zahrieh D., Agoura E., et al. Effect of up-front Daclizumab when combined with steroids for the treatment of acute graft vs. host disease: results of a randomized trial. Blood 104 (2004) 1559-1564
18. Ho V., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroids refractory acute graft versus host disease after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 1224-1226
19. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 23 (2005) 2661-2668
20. Apperley J.F., Jones L., Hale G., et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T cell depletion with Campath-1 reduces the incidence of graft versus host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant 1 (1986) 53-66
21. Kline J., Pollyea D.A., Stock W., et al. Pre-transplant ganciclovir and post transplant high dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 37 (2006) 307-310
22. Zerr D.M., Gooley T.A., Yeung L., et al. Human herpersvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis. 34 (2001) 309-317
23. Yoshikawa T., Asano Y., Ihira M., et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. J Infec Dis. 185 (2002) 847-853
24. Leung A.Y., Suen C.K., Lie A.K., et al. Quantification of polyoma BK virus in hemorrhagic cystitis complicating bone marrow transplantation. Blood 98 (2001) 1971-1978
25. Arthur R.R., Shah K.V., Baust S.J., et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Eng J Med. 315 (1986) 230-234
26. Apperley J.F., Rice S.J., and Bishop J.A. Late onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation 43 (1987) 108-112